"Analysis.group","Analysis.number","Analysis.name","Subgroup","Applicability","Study","Study.year","GIV.Mean","GIV.SE","Experimental.mean","Experimental.SD","Experimental.cases","Experimental.N","Control.mean","Control.SD","Control.cases","Control.N","O.E","Variance","Weight","Mean","CI.start","CI.end","Footnotes","review.url","review.doi","analysis_key","dataset_name","mismatch_type","direction_match","or_sig","rd_sig","log_or","rd","log_or_ci_lb","log_or_ci_ub","rd_ci_lb","rd_ci_ub","sparse_events","double_zero"
2,10,"Comparison 10 Vortioxetine versus placebo, Outcome 2 Acceptability","","SUBGROUP_AND_OVERALL","Mahableshwarkar 2014",2014,0,0,0,0,120,468,0,0,36,157,0,0,100,1.118234,0.807435,1.548665,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012942.pub2/full","10.1002/14651858.CD012942.pub2","10::overall","CD012942_pub2_data","significance_only",TRUE,TRUE,FALSE,0.325132809345782,0.0230806324484442,0.0620748032050916,0.588190815486472,-0.00501626031679752,0.0511775252136859,TRUE,TRUE
5,10,"Comparison 11 Vilazodone versus placebo, Outcome 4 Change in symptom levels","","SUBGROUP_AND_OVERALL","Gommol 2015",2015,0,0,-11.2,7.4,0,198,-9.9,7.5,0,197,0,0,100,-1.3,-2.769448,0.169448,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012942.pub2/full","10.1002/14651858.CD012942.pub2","10::overall","CD012942_pub2_data","significance_only",TRUE,TRUE,FALSE,0.325132809345782,0.0230806324484442,0.0620748032050916,0.588190815486472,-0.00501626031679752,0.0511775252136859,TRUE,TRUE
6,10,"Comparison 10 Vortioxetine versus placebo, Outcome 6 Total number of participants reporting adverse events","","SUBGROUP_AND_OVERALL","Mahableshwarkar 2014",2014,0,1.41448058206339,0,0,364,467,0,0,107,155,0,2.00075531703439,100,1.1291,1.005481,1.267917,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012942.pub2/full","10.1002/14651858.CD012942.pub2","10::overall","CD012942_pub2_data","significance_only",TRUE,TRUE,FALSE,0.325132809345782,0.0230806324484442,0.0620748032050916,0.588190815486472,-0.00501626031679752,0.0511775252136859,TRUE,TRUE
7,10,"Comparison 10 Vortioxetine versus placebo, Outcome 7 Sleepiness/drowsiness","","SUBGROUP_AND_OVERALL","Mahableshwarkar 2014",2014,0,0,0,0,28,467,0,0,6,155,0,0,100,1.548894,0.653599,3.670558,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012942.pub2/full","10.1002/14651858.CD012942.pub2","10::overall","CD012942_pub2_data","significance_only",TRUE,TRUE,FALSE,0.325132809345782,0.0230806324484442,0.0620748032050916,0.588190815486472,-0.00501626031679752,0.0511775252136859,TRUE,TRUE
11,10,"Comparison 10 Vortioxetine versus placebo, Outcome 11 Dropouts due to a lack of efficacy","","SUBGROUP_AND_OVERALL","Mahableshwarkar 2014",2014,0,0,0,0,7,468,0,0,4,157,0,0,100,0.587073,0.174173,1.978806,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012942.pub2/full","10.1002/14651858.CD012942.pub2","10::overall","CD012942_pub2_data","significance_only",TRUE,TRUE,FALSE,0.325132809345782,0.0230806324484442,0.0620748032050916,0.588190815486472,-0.00501626031679752,0.0511775252136859,TRUE,TRUE
12,10,"Comparison 10 Vortioxetine versus placebo, Outcome 12 Dropouts due to adverse effects","","SUBGROUP_AND_OVERALL","Mahableshwarkar 2014",2014,0,0,0,0,30,468,0,0,4,157,0,0,100,2.516026,0.900495,7.029891,"","https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012942.pub2/full","10.1002/14651858.CD012942.pub2","10::overall","CD012942_pub2_data","significance_only",TRUE,TRUE,FALSE,0.325132809345782,0.0230806324484442,0.0620748032050916,0.588190815486472,-0.00501626031679752,0.0511775252136859,TRUE,TRUE
